Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.
Front Immunol. 2024 Jul 15;15:1395854. doi: 10.3389/fimmu.2024.1395854. eCollection 2024.
Humanization is typically adopted to reduce the immunogenicity of murine antibodies generated by hybridoma technology when used in humans.
Two different strategies of antibody humanization are popularly employed, including "complementarity determining region (CDR) grafting" and "framework (FR) shuffling" to humanize a murine antibody against human programmed death-1 (PD-1), XM PD1. In CDR-grafting humanization, the CDRs of XM PD-1, were grafted into the human FR regions with high homology to the murine FR counterparts, and back mutations of key residues were performed to retain the antigen-binding affinities. While in FR-shuffling humanization, a combinatorial library of the six murine CDRs in-frame of XM PD-1 was constructed to a pool of human germline FRs for high-throughput screening for the most favorable variants. We evaluated many aspects which were important during antibody development of the molecules obtained by the two methods, including antibody purity, thermal stability, binding efficacy, predicted humanness, and immunogenicity, along with T cell epitope prediction for the humanized antibodies.
While the ideal molecule was not achieved through CDR grafting in this particular instance, FR-shuffling proved successful in identifying a suitable candidate. The study highlights FR-shuffling as an effective complementary approach that potentially increases the success rate of antibody humanization. It is particularly noted for its accessibility to those with a biological rather than a computational background.
The insights from this comparison are intended to assist other researchers in selecting appropriate humanization strategies for drug development, contributing to broader application and understanding in the field.
当在人类中使用时,杂交瘤技术产生的鼠源性抗体通常采用人源化来降低其免疫原性。
目前有两种常用的抗体人源化策略,包括“互补决定区(CDR)移植”和“框架(FR)改组”,用于人源化针对人程序性死亡受体-1(PD-1)的鼠源性抗体 XM PD1。在 CDR 移植人源化中,将 XM PD-1 的 CDRs 移植到与鼠 FR 同源性高的人 FR 区域,并进行关键残基的反向突变,以保留抗原结合亲和力。而在 FR 改组人源化中,构建了一个包含 XM PD-1 的六个鼠源性 CDRs 的组合文库,与大量人胚系 FR 进行高通量筛选,以获得最有利的变体。我们评估了通过这两种方法获得的分子在抗体开发过程中的许多重要方面,包括抗体纯度、热稳定性、结合效力、预测的人源化程度和免疫原性,以及对人源化抗体的 T 细胞表位预测。
虽然在这种特殊情况下,CDR 移植未能获得理想的分子,但 FR 改组成功地鉴定出了合适的候选物。该研究强调了 FR 改组作为一种有效的互补方法,可以提高抗体人源化的成功率。特别值得注意的是,它对于那些具有生物学背景而非计算背景的人来说更容易获得。
从这种比较中获得的见解旨在帮助其他研究人员为药物开发选择合适的人源化策略,为该领域的更广泛应用和理解做出贡献。